Compare Baxter International Inc (BAX) vs Church & Dwight Co., Inc. (CHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Baxter International Inc vs Church & Dwight Co., Inc. — how do they compare? Baxter International Inc trades at $27.61 (market cap $14.36B), while Church & Dwight Co., Inc. trades at $102.84 (market cap $24.50B). The key difference: Church & Dwight Co., Inc. is the larger of the two by market cap, and Church & Dwight Co., Inc. pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| BAX | CHD | |
|---|---|---|
Market Cap | $14.36B | $24.50B |
Sector | Health | Consumer Staples |
52-Week High | $28.35 | $105.26 |
52-Week Low | $15.80 | $81.60 |
Enterprise Value | $21.88B | $26.50B |
Dividend Yield | 0.14% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.55, up 2.0% today, showing strong momentum after recent earnings beats. The stock is approaching its 52-week high of $29.35, with technical indicators signaling bullish momentum. Fundamentally, the company reported Q2 2026 earnings of $0.56 per share, beating estimates, and raised full-year guidance, though profitability metrics remain negative with a -9.27% net income margin. Recent news highlights operational improvements and strong demand for IV solutions.
The outlook is cautiously optimistic as Baxter demonstrates turnaround progress with raised guidance and earnings beats. Investment opportunity lies in continued operational execution and margin recovery, but risks include persistent negative profitability, high debt levels, and competitive pressures in the medtech space. Wall Street sentiment is mixed with 42% buy ratings but a consensus price target below current levels.
Church & Dwight (CHD) trades at $103.24, slightly below the consensus price target of $103.57, with a modest 24-hour decline of 0.12%. The stock exhibits a bullish technical trend, supported by moving averages, while fundamentals show steady revenue growth to $6.20 billion in 2025 and a net income margin of 11.96%. Recent Q2 2026 earnings matched estimates with organic sales growth of 5.8%, prompting raised full-year guidance. Analyst sentiment is positive with 53% buy ratings, though valuation multiples like a P/E of 33.09 suggest premium pricing.
The outlook remains favorable due to strong brand performance and raised earnings guidance, but risks include elevated debt levels and competitive pressures in consumer staples. Institutional activity shows mixed positions, with some funds reducing stakes. The stock's upside is capped by high valuations, requiring sustained earnings growth to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Baxter International Inc
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →About Church & Dwight Co., Inc.
Church & Dwight is the leading producer of baking soda in the world. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Xtra, Trojan, OxiClean, First Response, Nair, L'il Critters/Vitafusion, Orajel, and WaterPik, which together with Arm & Hammer constitute more than 80% of its annual sales and profits. In early 2019, the firm announced the addition of Flawless, which manufactures electric shaving products for women. At the end of 2020, the firm acquired Zicam, a leading brand in the cough/cold-shortening category. Church & Dwight derives more than 80% of its sales from its home market in the U.S.
Read more on CHD →
